Trial Profile
The Relationship Between Neuropsychological Testing and MRI, PET and Blood Biomarkers in Neurodegenerative Disease (COBRE - Project 1): AIM 2
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs GEH 120714 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment; Parkinson's disease
- Focus Diagnostic use
- Acronyms AIM 2; COBRE - Project 1
- 29 Apr 2023 Status changed from recruiting to discontinued.
- 12 May 2022 Planned End Date changed from 31 May 2022 to 30 Jun 2026.
- 12 May 2022 Planned primary completion date changed from 31 May 2022 to 30 Jun 2026.